This week Lori, Greg and Tyler discuss <a href="https://www.biospace.com/article/drug-pricing-reforms-front-and-center-as-2024-election-ramps-up/" target="_blank" rel="noopener noreferer">drug pricing reforms</a>. CMS sent offers to manufacturers of the 10 drugs that have been selected for Medicare price negotiations. What&#39;s the best way forward that benefits patients while still supporting the innovation that makes these drugs possible? How will the election impact negotiations?
Also discussed earnings including <a href="https://www.biospace.com/article/novo-nordisk-gets-2023-profit-beat-fueled-by-ozempic-wegovy-sales-spike-/" target="_blank" rel="noopener noreferer">Novo Nordisk</a>, who beat analyst expectations largely due to sales of Ozempic and Wegovy, <a href="https://www.biospace.com/article/abbvie-gets-q4-revenue-beat-sees-2023-sales-decline-in-oncology-immunology/" target="_blank" rel="noopener noreferer">AbbVie</a>, <a href="https://www.biospace.com/article/merck-posts-60b-in-sales-for-2023-driven-by-keytruda-hpv-vaccine/" target="_blank" rel="noopener noreferer">Merck</a>, and <a href="https://www.biospace.com/article/gsk-sees-sales-uptick-in-2023-fueled-by-vaccines-for-rsv-and-shingles/" target="_blank" rel="noopener noreferer">GSK</a>.

Eyes on the prize: Novo buys Catalent

Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.